Biomarkers of Immunothrombosis and Polymorphisms of IL2, IL6, and IL10 Genes As Predictors of the Severity of COVID-19 in a Kazakh Population

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Jun 30

PMID 37390087

Authors

Assiya Yessenbayeva

Bakytbek Apsalikov

Meruyert Massabayeva

Maksut Kazymov

Aizhan Shakhanova

Zhanna Mussazhanova

Irina Kadyrova

Nurlan Aukenov

Nurlan Shaimardanov

Affiliations

Soon will be listed here.

Abstract

Objectives: To study the role of biological markers of immunothrombosis and polymorphisms of cytokine genes IL2, IL6, IL10 and their influence on the severity of COVID-19 in a Kazakh population.

Methods: A total of 301 patients of Kazakh nationality with a confirmed diagnosis of COVID-19 participated in the retrospective study, including 142 patients with severe and 159 with a mild course. Single nucleotide polymorphisms IL2R rs1801274, IL6 rs2069840, and IL10 rs1800872 were genotyped by real-time PCR. Activated partial thromboplastin time, normalized ratio, prothrombin index, prothrombin time, fibrinogen prothrombin time, fibrinogen, D-dimer, and C-reactive protein analysis were also conducted.

Results: The average age of patients with severe COVID-19 is higher than of patients with mild COVID-19 (p = 0.03). The findings showed that fibrinogen, D-dimer, and C-reactive protein were significantly greater in the group of patients with severe COVID-19 (p = 0.0001). A very strong correlation between the severity of COVID-19 with the D-dimer and C-reactive protein (p = 0.9) (p = 0.02) was found.

Conclusion: The results of our study confirm that D-dimer, fibrinogen, and CRP are biomarkers of inflammation and hypercoagulation that serve as predictors of immunothrombosis affecting the severity of COVID-19. D-dimer is also associated with IL10 rs1800872 gene polymorphism in the Kazakh population with severe COVID-19.

References

Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M . Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2020; 26(3):107-108. PMC: 7493072. DOI: 10.1136/bmjebm-2020-111536. View

Batur L, Hekim N . Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries. J Med Virol. 2021; 93(10):5853-5863. PMC: 8242628. DOI: 10.1002/jmv.27127. View

Zhang N, Wang S, Fan Y, Sheng C, Ge W . Association Between IL10 Polymorphisms and the Susceptibility to Sepsis: A Meta-Analysis. Biochem Genet. 2022; 61(3):847-860. DOI: 10.1007/s10528-022-10310-8. View

Bivona G, Agnello L, Ciaccio M . Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med. 2021; 41(6):540-548. PMC: 8203437. DOI: 10.3343/alm.2021.41.6.540. View

Abbood S, Anvari E, Fateh A . Association between interleukin-10 gene polymorphisms (rs1800871, rs1800872, and rs1800896) and severity of infection in different SARS-CoV-2 variants. Hum Genomics. 2023; 17(1):19. PMC: 9990970. DOI: 10.1186/s40246-023-00468-6. View

Avendano-Felix M, Ochoa-Ramirez L, Ramos-Payan R, Aguilar-Medina M, Ayala-Ham A, Rendon-Aguilar H . Lack of Effects of the Genetic Polymorphisms of Interleukin-10 in Clinical Outcomes of COVID-19. Viral Immunol. 2021; 34(8):567-572. DOI: 10.1089/vim.2021.0022. View

Lu L, Zhang H, Dauphars D, He Y . A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends Immunol. 2020; 42(1):3-5. PMC: 7605819. DOI: 10.1016/j.it.2020.10.012. View

Yildirim Z, Sahin O, Yazar S, Cetintas V . Genetic and epigenetic factors associated with increased severity of Covid-19. Cell Biol Int. 2021; 45(6):1158-1174. PMC: 8014716. DOI: 10.1002/cbin.11572. View

Hamet P, Pausova Z, Attaoua R, Hishmih C, Haloui M, Shin J . SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. Am J Hypertens. 2021; 34(4):367-376. PMC: 7799248. DOI: 10.1093/ajh/hpaa223. View

10.

Hasanvand A . COVID-19 and the role of cytokines in this disease. Inflammopharmacology. 2022; 30(3):789-798. PMC: 9064717. DOI: 10.1007/s10787-022-00992-2. View

11.

Rahimi P, Tarharoudi R, Rahimpour A, Amroabadi J, Ahmadi I, Anvari E . The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J. 2021; 18(1):221. PMC: 8590865. DOI: 10.1186/s12985-021-01692-z. View

12.

Anka A, Tahir M, Abubakar S, Alsabbagh M, Zian Z, Hamedifar H . Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020; 93(4):e12998. PMC: 7744910. DOI: 10.1111/sji.12998. View

13.

Contini C, Di Nuzzo M, Barp N, Bonazza A, De Giorgio R, Tognon M . The novel zoonotic COVID-19 pandemic: An expected global health concern. J Infect Dev Ctries. 2020; 14(3):254-264. DOI: 10.3855/jidc.12671. View

14.

Fang L, Karakiulakis G, Roth M . Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020; 8(4):e21. PMC: 7118626. DOI: 10.1016/S2213-2600(20)30116-8. View

15.

Varikasuvu S, Varshney S, Dutt N, Munikumar M, Asfahan S, Kulkarni P . D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies. Sci Rep. 2021; 11(1):21888. PMC: 8576016. DOI: 10.1038/s41598-021-01462-5. View

16.

Giannitrapani L, Augello G, Mirarchi L, Amodeo S, Veronese N, Lo Sasso B . Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population. J Infect. 2022; 85(2):174-211. PMC: 9050196. DOI: 10.1016/j.jinf.2022.04.043. View

17.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

18.

Fiolet T, Kherabi Y, MacDonald C, Ghosn J, Peiffer-Smadja N . Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2021; 28(2):202-221. PMC: 8548286. DOI: 10.1016/j.cmi.2021.10.005. View

19.

Han H, Yang L, Liu R, Liu F, Wu K, Li J . Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020; 58(7):1116-1120. DOI: 10.1515/cclm-2020-0188. View